New Research Findings on Functional Peptide “COSMEPEPTIN®”
Reported at Society of Cerebral-Cardio-Vascular Anti-Aging 2012

AnGes MG Inc. (“AnGes”) announced today that new functions of “COSMEPEPTIN®” were confirmed in a mechanism analysis and it will be announced at the conference held by the Society of Cerebral-Cardio-Vascular Anti-Aging (CCVAA) 2012, titled ‘Forefront and the Future of Anti-Aging Medical Science.’ COSMEPEPTIN® is the functional peptide that has been known to have anti-aging and antibacterial actions from previous researches.

COSMEPEPTIN® is an altered peptide of AG30, the functional peptide found through the gene function screening conducted at Osaka University. The first researches confirmed that it had antibacterial action and proliferation action toward fibroblast cells, and in the following mechanism analysis, it became evident that it had enhanced hyaluronic acid production action, anti-wrinkle action, and skin-sagging prevention action (collagen gel contraction). In addition to those findings, the further analysis indicated that it also had antioxidative action and hair growth promoting action (hair follicle papilla cell proliferative activity).

COSMEPEPTIN® stimulates dermal fibroblast proliferation and increases the production of hyaluronic acid, which decreases with aging and give vitality, elasticity and moisture to the skin. It is expected to improve wrinkles and skin-sagging by activating traction force of dermal fibroblast cells. It can also prevent bacteria-related skin problems by improving skin barrier functions with the action similar to antimicrobial peptide, an innate immune system. Furthermore, the newly identified antioxidative activity can suppress harmful active oxygen, and hair follicle papilla cell proliferative activity is expected to promote hair growth.

COSMEPEPTIN® has various anti-aging effects mediated by antibacterial action and effects on the fibroblast cells, therefore it is expected to be applied in the new types of cosmetic and healthcare products. In collaboration with a major cosmetic company and other organizations, AnGes is currently undertaking functional evaluations of COSMEPEPTIN® and the peripheral peptides, and is planning to pursue the commercialization promptly.
This trend will have no effect on the business performance for the fiscal year of 2012.

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.